By Marie Rosenthal, MS
Oral bridging (OB) of lenacapavir enabled patients to maintain viral suppression of their HIV after missing doses of subcutaneous lenacapavir (LEN; Sunlenca, Gilead), according to data presented at IAS 2023, the 12th Annual IAS Conference on HIV Science, held in Brisbane, Australia, and virtually.
In December 2021, the FDA imposed a full clinical hold of subcutaneous LEN because of glass vial compatibility concerns, explained Jean-Michel Molina, MD, Université